Is the US prepared to deal with another pandemic or widespread health crisis?

No, the US is not fully prepared for another pandemic or widespread health crisis, though it is better equipped in several concrete areas than before COVID-19. Significant gaps in coordination, sustained funding, workforce, state-level capacity, leadership structures, and implementation of lessons learned leave the nation vulnerable, with preparedness remaining uneven, fragile, and subject to political and budgetary shifts.[1]

Tangible Improvements Since COVID-19

Post-COVID efforts have addressed some critical weaknesses:

•Strategic National Stockpile (SNS) and medical countermeasures: The SNS now holds far more personal protective equipment (PPE) and equipment than pre-pandemic levels—reportedly around 70 times the N95 respirators, 34 times the gloves, 50 times the isolation gowns, and 10 times the ventilators. Investments via BARDA (Biomedical Advanced Research and Development Authority), Project BioShield, and related programs have advanced vaccines, therapeutics, and manufacturing capacity, including mRNA platforms for faster adaptation to new threats.[2]

•Surveillance and data systems: Electronic case reporting expanded dramatically (from fewer than 200 healthcare facilities pre-COVID to over 45,000–48,000 by late 2024). Syndromic surveillance covers most emergency departments, wastewater monitoring has grown, and tools like CDC’s Center for Forecasting and Outbreak Analytics support modeling. The “One CDC” data platform and related modernizations aim for better real-time sharing.[3]

•Institutional changes: The White House Office of Pandemic Preparedness and Response Policy (OPPR) was established in 2023 as a permanent coordinating body. CDC has reorganized for better readiness, created public-private “warm base” lab partnerships for rapid test development/surge capacity, and emphasized clearer communication. The US completed a second WHO Joint External Evaluation (JEE) in 2024 (using a post-COVID tool), scoring relatively strongly in many of the 19 technical areas (e.g., high in immunization, some lab/surveillance/response elements), while receiving recommendations for further improvement.[4]

•Other advances: Global health security investments (over $3 billion since 2020 in some tallies), restocking and distribution experience from COVID/mpox/H5N1 responses, nurse licensure compact adoption in most states for workforce mobility, and public health/emergency management accreditation in many jurisdictions. Biden administration roadmaps and playbooks documented these steps and left guidance for successors.[5]

These changes mean faster detection potential, better initial supply buffers, improved vaccine/tech platforms, and some clearer federal structures compared to early 2020.

Persistent and Recurring Gaps

Multiple independent assessments highlight that progress is incomplete and at risk:

•GAO findings: Hundreds of recommendations from COVID oversight remain open (e.g., ~220 of 428 as of mid-2024). Key high-risk areas include HHS leadership/coordination of public health emergencies. Lessons span planning, partner collaboration, clear communications, data sharing, program integrity, leveraging infrastructure, and flexibilities. Mpox response in 2022–2023 repeated challenges like vaccine/test access and coordination.[1]

•Bipartisan Commission on Biodefense (2024 National Blueprint): The US “remains dangerously vulnerable.” Despite some progress, fragmented efforts across 15+ departments/agencies are insufficient. It calls for stronger White House leadership (e.g., codifying National Security Advisor role and a deputy for biodefense), a quadrennial strategy review, sustained (not emergency-only) medical countermeasure funding to break the “panic-and-neglect” cycle, better indoor air/pathogen transmission defenses, intelligence/attribution, and full implementation of prior recommendations. Biological threats (natural, accidental, deliberate) are growing.[6]

•State and local variation (Trust for America’s Health “Ready or Not” reports): Preparedness is uneven. Recent editions place roughly 20 states in a high-performance tier, with others in middle or low (around 13 low) based on indicators like public health funding trends, lab surge plans, paid sick leave access, flu vaccination rates (often well below 70% targets), water safety, hospital safety grades, avoidable mortality, workforce mobility, and accreditation. Some states cut public health funding post-COVID supplemental expiration; federal funding instability compounds this. All states have room to improve.[7]

•Workforce, funding, and systems: Public health workforce faces declines, burnout, and retention issues despite temporary COVID investments. PAHPA (Pandemic and All-Hazards Preparedness Act) and related authorizations face appropriation shortfalls (e.g., multi-billion gaps projected for countermeasures). Supply chain resilience, antimicrobial resistance, health equity, and One Health (human-animal-environment) coordination remain challenges. Public trust erosion and politicization hinder response.[8]

•Ongoing tests like H5N1 avian influenza: Spread in birds, dairy cattle, and sporadic human cases (mostly mild occupational exposures, with limited deaths) has tested systems. Responses include stockpiling candidate vaccines, mRNA development funding, PPE distribution, and surveillance (e.g., milk testing), but experts note gaps in farmworker protections, integrated human-animal surveillance/data sharing, testing scale, and urgency—echoing concerns that COVID lessons are not fully internalized. Risk to the general public remains low currently, but mutation potential underscores needs.[9]

•Broader context: JEE and other reviews recommend better alignment of frameworks across federal/state/local/tribal/territorial levels, addressing local capacity gaps, monitoring workforce investments, and reviewing funding efficiency/fragmentation. Global preparedness is also mixed/fragile (e.g., WHO efforts like the Pandemic Agreement). Domestic political transitions can disrupt continuity, funding, or priorities (e.g., research oversight, agency capacity).

Bottom Line and Path Forward

The US has stronger tools, stockpiles, data infrastructure, and some institutional muscle memory than in 2019–2020, enabling a potentially faster and more effective initial response in many scenarios. However, it is not fully prepared. Success against a severe novel pathogen (especially one more transmissible/lethal than early SARS-CoV-2, or concurrent with other disasters) would still depend heavily on rapid political will, sustained resources, effective multi-level coordination, clear trusted communication, equitable access, and avoiding past bottlenecks. Vulnerabilities in leadership cohesion, chronic underinvestment outside crises, state disparities, and trust could again amplify impacts.

Experts and reports consistently urge: sustained (not boom-bust) funding for core public health and biodefense; stronger centralized yet flexible leadership/coordination; workforce investment and surge capacity; full GAO/Blueprint recommendation implementation; modernized One Health surveillance; resilient supply chains and domestic manufacturing; equity-focused planning; and regular exercises/after-action learning. Reauthorizing and fully funding key laws like PAHPA, maintaining OPPR and related offices, and bipartisan commitment are frequently cited priorities. Preparedness is a continuous process, not a one-time achievement—current trajectory shows progress but incomplete and reversible gains.

Citations (9)

1gao.govGovernment
https://www.gao.gov/products/gao-24-107175
Backs: “Significant gaps in coordination, sustained funding, workforce, state-level capacity, leadership structures, and implementation of lessons learned leave the nation vulnerable, with preparedness remaining uneven, fragile, and subject to political and budgetary shifts.”
evidence, official document, points to no. Claim: US is not fully prepared; GAO notes many open COVID recommendations, HHS coordination as high-risk area, and mpox response repeating challenges.
2archives.govGovernment
https://bidenwhitehouse.archives.gov/briefing-room/statements-releases/2025/01/14/report-the-biden-harris-administration-roadmap-for-pandemic-preparedness-and-response/
Backs: “Investments via BARDA (Biomedical Advanced Research and Development Authority), Project BioShield, and related programs have advanced vaccines, therapeutics, and manufacturing capacity, including mRNA platforms for faster adaptation to new threats.”
statistic, official document, points to yes. Claim: SNS holds far more PPE and equipment than pre-pandemic (70x N95s, etc.); BARDA investments advanced vaccines, therapeutics, mRNA platforms.
3cdc.govGovernment
https://www.cdc.gov/washington/testimony/2024/t20241114.htm
Backs: “The “One CDC” data platform and related modernizations aim for better real-time sharing.”
statistic, official document, points to yes. Claim: Electronic case reporting expanded from under 200 facilities to 45,000+; syndromic surveillance, wastewater monitoring, forecasting center improvements.
4who.intGovernment
https://www.who.int/publications/i/item/9789240105409
Backs: “The US completed a second WHO Joint External Evaluation (JEE) in 2024 (using a post-COVID tool), scoring relatively strongly in many of the 19 technical areas (e.g., high in immunization, some lab/surveillance/response elements), while receiving recommendations for further improvement.”
evidence, official document, points to yes. Claim: US completed second WHO Joint External Evaluation in 2024, scoring strongly in many technical areas while receiving improvement recommendations.
5ucsb.eduAcademic
https://www.presidency.ucsb.edu/documents/fact-sheet-biden-harris-administration-releases-global-health-security-annual-report
Backs: “Biden administration roadmaps and playbooks documented these steps and left guidance for successors.”
evidence, official document, points to yes. Claim: Global health security investments exceeding $3 billion since 2020 and administration documentation of steps taken.
6biodefensecommission.orgNonprofits and think tanks
https://biodefensecommission.org/reports/the-national-blueprint-for-biodefense/
Backs: “Biological threats (natural, accidental, deliberate) are growing.”
attribution, official document, points to no. Claim: Bipartisan Commission on Biodefense says US remains dangerously vulnerable, with fragmented efforts and need for stronger leadership and sustained funding.
7tfah.orgNonprofits and think tanks
https://www.tfah.org/article/new-report-measures-states-preparedness-for-public-health-emergencies-including-infectious-disease-outbreaks-and-extreme-weather-events/
Backs: “Some states cut public health funding post-COVID supplemental expiration; federal funding instability compounds this. All states have room to improve.”
evidence, article, points to no. Claim: TFAH reports show uneven state preparedness, with about 20 states high-performing and about 13 low, and funding cuts in some states.
8center-forward.orgNonprofits and think tanks
https://center-forward.org/basic/pandemic-preparedness-strengthening-the-u-s-response-framework-2/
Backs: “Supply chain resilience, antimicrobial resistance, health equity, and One Health (human-animal-environment) coordination remain challenges. Public trust erosion and politicization hinder response.”
evidence, article, points to no. Claim: Public health workforce declines, PAHPA funding shortfalls, supply chain, and trust challenges hinder preparedness.
9nejm.orgAcademic
https://www.nejm.org/doi/full/10.1056/NEJMp2406427
Backs: “Risk to the general public remains low currently, but mutation potential underscores needs.”
evidence, article, points to no. Claim: H5N1 response shows gaps in farmworker protection, integrated surveillance, testing scale, and urgency despite stockpiling and mRNA efforts.